Profusa (NASDAQ:PFSA) Stock to Reverse Split on Monday, August 17th

Profusa, Inc. (NASDAQ:PFSA)’s stock is scheduled to reverse split before the market opens on Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 16th.

Profusa Stock Performance

NASDAQ:PFSA traded down $0.01 during trading hours on Thursday, reaching $0.95. The company’s stock had a trading volume of 197,899 shares, compared to its average volume of 624,052. The stock has a 50 day moving average price of $2.85 and a two-hundred day moving average price of $25.06. Profusa has a 12 month low of $0.81 and a 12 month high of $1,297.50.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PFSA shares. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.